22 citations
,
November 2021 in “Dermatology and Therapy” The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
20 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
4 citations
,
December 2020 Methotrexate may help stabilize frontal fibrosing alopecia.
1 citations
,
May 2026 in “Journal of Dermatological Treatment” JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
1 citations
,
November 2025 in “International Journal of Dermatology” The AAcQLI is a promising tool for assessing quality of life in children with alopecia areata.
1 citations
,
July 2018 in “Journal of Pakistan Association of Dermatology” Microneedling with PRP is a safe and effective way to treat chronic alopecia areata, improving hair regrowth with minimal side effects.
July 2026 in “Mendeley Data” Dupilumab can cause either hair regrowth or hair loss in alopecia areata patients.
July 2026 in “Mendeley Data” Dupilumab can cause either hair regrowth or hair loss in alopecia areata patients.
May 2026 in “Actas Dermo-Sifiliográficas” Effective treatments exist for hair loss, and a new guide helps doctors choose the best one.
May 2026 in “International Journal of Homoeopathic Sciences” Individualized Homeopathic Medicine shows promise for treating alopecia with lasting hair regrowth.
March 2026 in “Pediatric Dermatology” Generative AI tools can accurately score alopecia areata, reducing subjectivity in evaluations.
The treatment with Bakuchiol and Neem oil significantly improved hair growth and was well-received by most participants.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
January 2024 in “Skin appendage disorders” Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
January 2024 in “International Journal of Advanced Computer Science and Applications” Deep learning and explainable AI are improving scalp disorder diagnosis, but challenges in transparency and data quality remain.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
May 2022 in “Journal of the American Academy of Dermatology” The document suggests using a topical Vitamin D treatment for hair loss rather than oral supplements and calls for more research.
January 2018 in “Skin appendage disorders” The document focused on hair disorders, especially alopecia, and discussed treatments and impacts on quality of life.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.